Ethics approval

This study was conducted in accordance with the principles of the 1964 Declaration of Helsinki and its subsequent amendments, as well as the institutional ethical standards.

Consent for publication

The authors affirm that the patient provided written informed consent for publication of the images.

Consent to participate

The authors affirm that the patient provided written informed consent prior to the procedure and the scientific evaluation of the data.

Competing interests

Johannes Notni is co-inventor of patents related to αvβ6-integrin targeted radiopharmaceuticals; co-founder, shareholder, and CEO of TRIMT GmbH (Radeberg, Germany). Michael C. Kreissl is advisor of TRIMT GmbH. All other authors declare that they have no competing interests.